Oncology News | pharmaphorum

News

AZ’s Calquence extends disease-free survival in MCL

AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival

News

FDA widens label for BMS’ cancer drug Augtyro

Bristol-Myers Squibb has claimed FDA approval for a new, tumour-agnostic indication for Augtyro, the cancer drug it acquired as part of its $4.1 billion takeover of Turning Point Therapeuti

News

GSK et al file appeal to Delaware Zantac order

GSK and other drugmakers have lost no time in filing an appeal to a Delaware court’s decision to allow more than 70,000 Zantac-related lawsuits to go ahead.

News

Close-up view of an actinic keratosis lesion

FDA OKs wider use of Almirall’s actinic keratosis drug

With actinic keratosis (AK) diagnoses on the rise, there is some good news for patients, with the FDA approval of expanded use of Almirall’s topical therapy Klisyri.

News

Geron finally brings a drug to market as FDA clears Rytelo

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.

News

Telix prices $200m IPO in big week for radiopharma financing

Australian radiopharmaceutical specialist Telix has revealed the terms of its planned initial public offering (IPO) in the US, revealing that it hopes to raise $202 millio

AZ’s Calquence extends disease-free survival in MCL

FDA widens label for BMS’ cancer drug Augtyro

GSK et al file appeal to Delaware Zantac order

FDA OKs wider use of Almirall’s actinic keratosis drug

Geron finally brings a drug to market as FDA clears Rytelo

Telix prices $200m IPO in big week for radiopharma financing

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks